{"disease":{"id":"prednisone","name":"prednisone"},"drugs":{"marketed":[{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma - Melphalan/Prednisone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02252237","title":"Pharmacokinetics of Glucocorticoids in Children (GLUCOPED)","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06251232","title":"Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","has_results":false},{"nct_id":"NCT03470311","title":"Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT05649878","title":"Evaluation of the Bioavailability of Methylprednisolone","phase":"NA","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Edda Sciutto Conde","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}